AntriaBio, Inc. Announces Board of Director Appointments
March 22, 2017 at 08:00 am EDT
Share
AntriaBio, Inc. announced the appointment of Tae Hoon Kim and Samir R. Patel, M.D. to its Board of Directors. Mr. Kim and Dr. Patel join AntriaBio's Board as the company prepares to conduct the first-in-human clinical study for its lead product candidate, AB101, a once-weekly basal insulin in development for patients with type 1 and type 2 diabetes. Mr. Kim brings to the Board a wealth of experience from his time at Genentech, Inc. and most recently as Chief Operating Officer at Aju Pharm. Dr. Patel is co-founder, principal and former CEO of SPEC Pharma, LLC, which specializes in injectable therapies with complex manufacturing. He is also co-founder, principal and CEO of Digital Therapeutics, LLC. Dr. Patel previously served as Medical Director of Centocor, Inc. where he oversaw Medical Affairs for Remicade, Stelara and Simponi.
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Companyâs lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
REZOLUTE, INC. 
